Slingshot members are tracking this event:

Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AMGN Community voting in process

Additional Information

Additional Relevant Details During the meeting, Amgen will present a comprehensive data package which supports biosimilarity of ABP 501 to adalimumab based on analytical, nonclinical, clinical and pharmacokinetic data, including results from two Phase 3 studies conducted in moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis. The Phase 3 studies met their primary endpoints showing clinical comparability to adalimumab. Safety and immunogenicity of ABP 501 were also comparable to adalimumab.  
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 12, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Adalimumab, Abp 501, Bla, Humira, Inflammatory Disease